Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

24.30 -0.67 (-2.68%)
Streaming Delayed Price Updated: 1:52 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
ACADIA Pharmaceuticals: Q2 Earnings Insights ↗
  ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗
  
Via Benzinga
News headline image
8 Analysts Have This to Say About ACADIA Pharmaceuticals ↗
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: 
Via Benzinga
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions ↗
 
Via Benzinga
News headline image
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today? ↗
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5 ↗
CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report 
Via Benzinga
News headline image
Why Acadia Pharma Shares Are Plunging Today ↗
 
Via Benzinga
News headline image
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? ↗
 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap of Monday's Biotech Catalysts - End of the Day Summary ↗
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
News headline image
Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate ↗
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome. 
Via Benzinga
News headline image
Where ACADIA Pharmaceuticals Stands With Analysts ↗
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: 
Via Benzinga
News headline image
Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis ↗
HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&# 
Via Benzinga
News headline image
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. 
Via Benzinga
News headline image
67 Biggest Movers From Yesterday ↗
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
News headline image
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday. 
Via Benzinga
News headline image
45 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
News headline image
U.S. Markets Open Higher; Lennar Earnings Top Views ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug ↗
It's not looking good for Nuplazid in Alzheimer's disease psychosis. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate ↗
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. 
Via Benzinga
News headline image
71 Biggest Movers From Yesterday ↗
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration... 
Via Benzinga
News headline image
Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug ↗
There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday. 
Via Investor's Business Daily
News headline image
55 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.